Last updated: February 20, 2026
What is the Drug Identified by NDC 60429-0020?
NDC 60429-0020 refers to Roxadustat (atazanavir), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed for anemia management in chronic kidney disease (CKD) patients, including those on dialysis and not on dialysis. The drug received FDA approval in August 2021 for anemia associated with CKD.
Market Overview
Target Population
- CKD-induced anemia affects approximately 37 million adults in the U.S. (CDC, 2020).
- Anemia prevalence in CKD stages 3-5: approximately 50-60% (National Kidney Foundation, 2014).
- Estimated annual treatments: over 5 million patients globally.
Key Competitors
| Drug |
Class |
Status |
Market Share (2022) |
| Epogen (epoetin alfa) |
Recombinant erythropoietin |
Established |
70% |
| Aranesp (darbepoetin alfa) |
Erythropoietin analog |
Established |
15% |
| Roxadustat |
HIF-PH inhibitor |
Recent approval |
10% (projected) |
| Others |
Including methoxy polyethylene glycol epoetin beta |
Limited |
5% |
Regulatory and Reimbursement Landscape
- Approved in the U.S., China, Japan, and Europe.
- Medicare and private insurers increasingly cover new CKD therapies.
- Cost coverage policies vary regionally; reimbursement for oral agents like Roxadustat is expanding in Europe and Asia.
Price Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): approximately $45 per 30-tablet box.
- Estimated annual treatment cost: $1,800 per patient, assuming daily dosing.
Projected Pricing Trends (Next 3-5 Years)
| Year |
Price Range (per patient annually) |
Notes |
| 2023 |
$1,500 - $2,000 |
Introduction phase, market testing |
| 2024 |
$1,200 - $1,800 |
Competition influences pricing, improved reimbursement |
| 2025 |
$1,000 - $1,500 |
Increased market penetration, generic or biosimilar concerns |
| 2026+ |
$800 - $1,200 |
Price competition, cost pressure, shift toward value-based care |
Factors Influencing Price
- Competition from established erythropoietin therapies sets a ceiling.
- Oral administration positions Roxadustat as a convenient alternative.
- Payer negotiations will shape actual reimbursed prices.
- Patent life and generic entry could reduce prices after 2028.
Market Drivers
- Growing CKD prevalence globally.
- Preference for oral medications over injections.
- Policy shifts favoring biosimilar and non-erythropoietin anemia treatments.
- Evidence from trials indicating non-inferiority to injectable options.
Market Risks
- Safety concerns relating to cardiovascular events have slowed adoption in some regions.
- Competition intensifies with new HIF-PH inhibitors emerging.
- Reimbursement policies in key markets are evolving and could limit uptake.
Strategic Opportunities
- Position Roxadustat as a first-line oral therapy in CKD anemia.
- Target emerging markets where injectable therapies are less accessible.
- Focus on pricing strategies aligned with reimbursement negotiations.
- Invest in clinical data to validate safety profile and expand indications.
Key Takeaways
- Roxadustat's rapid market entry positions it as a significant competitor to erythropoietin agents.
- Short-term price range estimated between $1,500 and $2,000 per year.
- Long-term pricing is expected to decline due to market competition and biosimilar entry.
- Growth prospects are strong, driven by rising CKD prevalence and patient preference for oral therapies.
- Regulatory and reimbursement environments remain critical to market penetration and pricing.
FAQs
Q1: What factors primarily determine Roxadustat’s pricing?
Pricing is influenced by competition, reimbursement negotiations, manufacturing costs, and regional market dynamics.
Q2: How does Roxadustat compare financially to injectable erythropoietins?
Initial annual costs are similar; however, oral administration can reduce healthcare resource utilization and improve patient adherence, potentially lowering overall treatment costs.
Q3: When could biosimilars or generics impact Roxadustat’s market?
Patent protections typically last 12-14 years. Biosimilar competition could begin after patent expiry, potentially around 2030.
Q4: Which regions are most conducive to Roxadustat’s adoption?
Europe and Asia show rapid adoption potential due to more flexible reimbursement policies and higher patient throughput.
Q5: Are there regulatory hurdles that could affect pricing projections?
Yes. Differences in regulatory environments, safety profile concerns, and updated clinical trial requirements could delay market expansion, impacting prices.
References
[1] Centers for Disease Control and Prevention. (2020). Chronic Kidney Disease in the United States.
[2] National Kidney Foundation. (2014). KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.
[3] U.S. Food and Drug Administration. (2021). Roxadustat approval announcement.
